Figure 5.

MYST1 silencing downregulates EGFR signaling pathway. A, The analysis of MYST1 expression in different subtypes of GBM from a TCGA cohort titled Tumor Glioblastoma TCGA‐540‐MAS5.0‐u133a in the R2 microarray analysis and visualization platform. B, The analysis of MYST1 expression in different subtypes of GBM from TCGA—Glioblastoma Affymetrix HT HG U133A were obtained from Betastasis (http://www.betastasis.com/). C‐E, The correlations of two genes analysis in in a TCGA cohort titled Tumor Glioblastoma TCGA‐540‐MAS5.0‐u133a from the R2 microarray analysis and visualization platform. F, Western blots of proteins expression in EGFR signaling pathways in LN229, U87 and A172 cells after MYST1/GFP silencing. G, Western blots of proteins expression in EGFR signaling pathways in indicated tumors obtained from the nude mice. H, qRT‐PCR analysis of EGFR expression after MYST1 knockdown. Experimental data were used as mean ± SD, n ≥ 3, significant difference was tested by Student's t test. n.s.= no sense. P < .05 was considered as statistically significant. EGFR, epidermal growth factor receptor; GBM, glioblastoma; GFP, green fluorescent protein